Considering the early-onset breast cancer risk in TP53 P/LP variant carriers, most guidelines recommend an annual breast MRI with and without contrast from the ages of 20–29, annual MRI and mammography screening between the ages of 30 and 75, and individualized screening after 75 years [6,40,148]. This evidence concerns the gene TP53 and breast carcinoma.